# Abbott Laboratories (ABT) financials

Abbott Laboratories reported revenue of $44.3 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 5.7% from fiscal 2024. Net income was $6.52 billion and diluted earnings per share $3.72.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $13.0 billion, up 14.5% from a year earlier.

Source: Abbott Laboratories's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 4 Nov 2026. Amounts in USD. Page: https://aapwire.com/stocks/ABT. Retrieved 2026-11-16.

## Latest results: Q3 FY2026

Abbott Laboratories reported revenue of $13.0 billion, up 14.5% from a year earlier, net income of $920 million and diluted earnings per share of $0.53 against $0.94 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, filed 4 Nov 2026.

| Measure | Q3 FY2026 | Q3 FY2025 | Change |
| --- | ---: | ---: | ---: |
| Revenue | $13.01B | $11.37B | +14.5% |
| Gross profit | $7.38B | $6.29B | +17.3% |
| Gross margin | 56.8% | 55.4% | +1.4 pts |
| Operating income | $1.36B | $2.06B | −34.0% |
| Operating margin | 10.4% | 18.1% | −7.7 pts |
| Net income | $920.0M | $1.64B | −44.0% |
| Diluted EPS | $0.53 | $0.94 | −43.6% |
| Operating cash flow | $1.74B | $2.79B | −37.7% |
| Capital expenditure | $513.0M | $496.0M | +3.4% |
| Free cash flow | $1.22B | $2.29B | −46.6% |

Page: https://aapwire.com/stocks/ABT/earnings

## Annual figures (fiscal years)

| Measure | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $20.85B | $27.39B | $30.58B | $31.90B | $34.61B | $43.08B | $43.65B | $40.11B | $41.95B | $44.33B |
| Revenue growth | +2.2% | +31.3% | +11.6% | +4.3% | +8.5% | +24.5% | +1.3% | −8.1% | +4.6% | +5.7% |
| Gross profit | $11.76B | $14.98B | $17.87B | $18.67B | $19.61B | $24.54B | $24.51B | $22.13B | $23.24B | $25.01B |
| Operating income | $3.03B | $1.56B | $3.65B | $4.53B | $5.36B | $8.43B | $8.36B | $6.48B | $6.83B | $8.05B |
| Net income | $1.40B | $477.0M | $2.37B | $3.69B | $4.50B | $7.07B | $6.93B | $5.72B | $13.40B | $6.52B |
| Diluted EPS | $0.94 | $0.27 | $1.33 | $2.06 | $2.50 | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 |
| Operating cash flow | $3.20B | $5.57B | $6.30B | $6.14B | $7.90B | $10.53B | $9.58B | $7.26B | $8.56B | $9.57B |
| Capital expenditure | $1.12B | $1.14B | $1.39B | $1.64B | $2.18B | $1.89B | $1.78B | $2.20B | $2.21B | $2.17B |
| Free cash flow | $2.08B | $4.43B | $4.91B | $4.50B | $5.72B | $8.65B | $7.80B | $5.06B | $6.35B | $7.39B |
| Gross margin | 56.4% | 54.7% | 58.4% | 58.5% | 56.6% | 57.0% | 56.1% | 55.2% | 55.4% | 56.4% |
| Operating margin | 14.5% | 5.7% | 11.9% | 14.2% | 15.5% | 19.6% | 19.2% | 16.2% | 16.3% | 18.2% |
| Net margin | 6.7% | 1.7% | 7.7% | 11.6% | 13.0% | 16.4% | 15.9% | 14.3% | 31.9% | 14.7% |
| Cash and equivalents | $18.62B | $9.41B | $3.84B | $3.86B | $6.84B | $9.80B | $9.88B | $6.90B | $7.62B | $8.52B |
| Total debt | $22.01B | $27.92B | $19.57B | $19.10B | $19.89B | $19.25B | $17.95B | $15.87B | $15.28B | $14.14B |
| Shareholders' equity | $20.54B | $30.90B | $30.52B | $31.09B | $32.78B | $35.80B | $36.69B | $38.60B | $47.66B | $52.13B |
| Diluted shares | 1.5B | 1.7B | 1.8B | 1.8B | 1.8B | 1.8B | 1.8B | 1.7B | 1.7B | 1.7B |
| Dividends per share | — | — | — | — | — | — | $1.92 | $2.08 | $2.24 | $2.40 |

## Quarterly figures (last eight fiscal quarters)

| Measure | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $10.97B | $10.36B | $11.14B | $11.37B | $11.46B | $11.16B | $12.59B | $13.01B |
| Revenue, year on year | +7.2% | +4.0% | +7.4% | +6.9% | +4.4% | +7.8% | +13.0% | +14.5% |
| Gross margin | 55.0% | 56.9% | 56.4% | 55.4% | 57.0% | 56.2% | 57.7% | 56.8% |
| Operating income | $1.91B | $1.69B | $2.05B | $2.06B | $2.25B | $1.34B | $1.69B | $1.36B |
| Net income | $9.23B | $1.32B | $1.78B | $1.64B | $1.78B | $1.08B | $928.0M | $920.0M |
| Diluted EPS | $5.28 | $0.76 | $1.01 | $0.94 | $1.03 | $0.61 | $0.53 | $0.53 |
| Free cash flow | $2.15B | $933.0M | $1.54B | $2.29B | $2.63B | $916.0M | $1.99B | $1.22B |

## Operating KPIs

| KPI | Latest | Period | Change on a year |
| --- | ---: | --- | --- |
| [Diabetes Care revenue](https://aapwire.com/stocks/ABT/kpi/diabetes-care-revenue) | $2.2B | quarter to 30 Sep 2026 | up 6.2% |
| [Core Laboratory revenue](https://aapwire.com/stocks/ABT/kpi/core-laboratory-revenue) | $1.4B | quarter to 30 Sep 2026 | up 5.4% |
| [Adult Nutritionals revenue](https://aapwire.com/stocks/ABT/kpi/adult-nutritionals-revenue) | $1.2B | quarter to 30 Sep 2026 | up 2.0% |
| [Key Emerging Markets revenue](https://aapwire.com/stocks/ABT/kpi/key-emerging-markets-revenue) | $1.2B | quarter to 30 Sep 2026 | up 8.9% |
| [Pediatric Nutritionals revenue](https://aapwire.com/stocks/ABT/kpi/pediatric-nutritionals-revenue) | $1.1B | quarter to 30 Sep 2026 | up 8.8% |
| [Cancer Diagnostics revenue](https://aapwire.com/stocks/ABT/kpi/cancer-diagnostics-revenue) | $968.0M | quarter to 30 Sep 2026 | — |
| [Rapid and Molecular revenue](https://aapwire.com/stocks/ABT/kpi/rapid-and-molecular-revenue) | $899.0M | quarter to 30 Sep 2026 | up 1.1% |
| [Electrophysiology revenue](https://aapwire.com/stocks/ABT/kpi/electrophysiology-revenue) | $873.0M | quarter to 30 Sep 2026 | up 14.9% |
| [Vascular revenue](https://aapwire.com/stocks/ABT/kpi/vascular-revenue) | $786.0M | quarter to 30 Sep 2026 | up 5.5% |
| [Rhythm Management revenue](https://aapwire.com/stocks/ABT/kpi/rhythm-management-revenue) | $752.0M | quarter to 30 Sep 2026 | up 9.6% |
| [Rapid Diagnostics revenue](https://aapwire.com/stocks/ABT/kpi/rapid-diagnostics-revenue) | $697.0M | quarter to 31 Dec 2025 | down 17.9% |
| [Structural Heart revenue](https://aapwire.com/stocks/ABT/kpi/structural-heart-revenue) | $592.0M | quarter to 30 Sep 2026 | up 2.1% |
| [Heart Failure revenue](https://aapwire.com/stocks/ABT/kpi/heart-failure-revenue) | $387.0M | quarter to 30 Sep 2026 | up 5.7% |
| [Neuromodulation revenue](https://aapwire.com/stocks/ABT/kpi/neuromodulation-revenue) | $251.0M | quarter to 30 Sep 2026 | down 1.2% |
| [Point of Care revenue](https://aapwire.com/stocks/ABT/kpi/point-of-care-revenue) | $158.0M | quarter to 31 Dec 2025 | up 7.5% |
| [Molecular revenue](https://aapwire.com/stocks/ABT/kpi/molecular-revenue) | $141.0M | quarter to 31 Dec 2025 | up 2.9% |
| [COVID-19 Testing revenue](https://aapwire.com/stocks/ABT/kpi/covid-19-testing-revenue) | $69.0M | quarter to 30 Sep 2025 | down 74.0% |
| [Medical Devices revenue](https://aapwire.com/stocks/ABT/kpi/medical-devices-revenue) | $5.8B | quarter to 30 Sep 2026 | up 6.9% |
| [Diagnostic Products revenue](https://aapwire.com/stocks/ABT/kpi/diagnostic-products-revenue) | $3.3B | quarter to 30 Sep 2026 | up 46.7% |
| [Nutritional Products revenue](https://aapwire.com/stocks/ABT/kpi/nutritional-products-revenue) | $2.3B | quarter to 30 Sep 2026 | up 5.1% |
| [Established Pharmaceuticals revenue](https://aapwire.com/stocks/ABT/kpi/established-pharmaceuticals-revenue) | $1.6B | quarter to 30 Sep 2026 | up 6.8% |

## Method

Each period is read from the report the company filed and checked against accounting identities; a figure that does not pass is left blank (—), never estimated. Free cash flow is operating cash flow less capital expenditure. Diluted EPS is as the company reported it, adjusted for later stock splits. Research information only, not investment advice.
